Innovation1 Biotech Stock Analysis
| IVBT Stock | USD 0 0.00 0.00% |
Innovation1 Biotech is overvalued with Real Value of 8.4E-4 and Hype Value of 0.001. The main objective of Innovation1 Biotech otc analysis is to determine its intrinsic value, which is an estimate of what Innovation1 Biotech is worth, separate from its market price. There are two main types of Innovation1 Biotech's stock analysis: fundamental analysis and technical analysis.
The Innovation1 Biotech otc stock is traded in the USA on OTCQB Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Innovation1 |
Innovation1 OTC Stock Analysis Notes
About 75.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.05. Some equities with similar Price to Book (P/B) outperform the market in the long run. Innovation1 Biotech recorded earning per share (EPS) of 5.54. The entity last dividend was issued on the 12th of January 2021. Innovation1 Biotech Inc. operates as a small molecule drug discovery company. The company was founded in 2014 and is based in New York, New York. Innovation1 Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.The quote for Innovation1 Biotech is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To learn more about Innovation1 Biotech call Jeffrey Kraws at 646-380-1923 or check out https://www.innovation1bio.com.Innovation1 Biotech Investment Alerts
| Innovation1 Biotech generated a negative expected return over the last 90 days | |
| Innovation1 Biotech has some characteristics of a very speculative penny stock | |
| Innovation1 Biotech currently holds 554.4 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Innovation1 Biotech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation1 Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation1 Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation1 Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation1 to invest in growth at high rates of return. When we think about Innovation1 Biotech's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (40.88 M) with loss before overhead, payroll, taxes, and interest of (17 K). | |
| Innovation1 Biotech currently holds about 636.16 K in cash with (3.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 75.0% of Innovation1 Biotech shares are held by company insiders |
Innovation1 Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.5 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Innovation1 Biotech's market, we take the total number of its shares issued and multiply it by Innovation1 Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
Innovation1 Biotech technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We have analyzed zero technical drivers for Innovation1 Biotech, which can be compared to its competitors.Innovation1 Biotech Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Innovation1 Biotech middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Innovation1 Biotech. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
About Innovation1 OTC Stock Analysis
OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Innovation1 Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Innovation1 shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as Innovation1 Biotech. By using and applying Innovation1 OTC Stock analysis, traders can create a robust methodology for identifying Innovation1 entry and exit points for their positions.
Innovation1 Biotech Inc. operates as a small molecule drug discovery company. The company was founded in 2014 and is based in New York, New York. Innovation1 Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Innovation1 Biotech to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
| All Next | Launch Module |
Additional Tools for Innovation1 OTC Stock Analysis
When running Innovation1 Biotech's price analysis, check to measure Innovation1 Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation1 Biotech is operating at the current time. Most of Innovation1 Biotech's value examination focuses on studying past and present price action to predict the probability of Innovation1 Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation1 Biotech's price. Additionally, you may evaluate how the addition of Innovation1 Biotech to your portfolios can decrease your overall portfolio volatility.